Gentile, Luca
Russo, Massimo
Rodolico, Carmelo
Arimatea, Ilenia
Vita, Giuseppe
Toscano, Antonio
Mazzeo, Anna
Article History
Received: 22 February 2021
Accepted: 16 April 2021
First Online: 28 April 2021
Competing interests
: Luca Gentile is sub-investigator in clinical trials of Alnylam, Ionis, Takeda. He also reports trav-el grants from Kedrion and CSL Behring to attend scientific meeting and acknowledge speaker fee and consulting honoraria from Pfizer. Massimo Russo acknowledges receiving speaker fee and consulting honoraria from Akcea and Alnylam and a travel grant from Pfizer. Anna Mazzeo is Principal Investigator in clinical trials of Alnylam and Ionis, sub-investigator in clinical trials of Alnylam, Ionis, Takeda. She also re-ports travel grants from Kedrion and CSL Behring to attend scientific meeting and acknowledge speaker fee and consulting honoraria from Alnylam, Akcea and Pfizer. Giuseppe Vita is Princi-pal Investigator in clinical trials of Roche, Sarepta, Santhera, Italfarmaco, Biogen, Avexis, Al-nylam, Ionis, Wave. He is also consulent of Advisory Board for Roche, Avexis, Alnylam, Akcea and he acknowledges speaker fee and consulting honoraria from Alnylam, Akcea and Pfizer. Antonio Toscano is Principal Investigator in clinical trials of Takeda and Genzyme. He acknowledges speaker fee and consulting honoraria from Kedrion, CSL Behring and Genzyme. Carmelo Rodolico and Ilenia Arimatea declare no competing interests.